Satellos Bioscience Inc. announced positive preclinical data showing SAT-3247 can improve skeletal muscle function in multiple mouse models of muscle degeneration. The preclinical data presented show the broad potential of SAT-3247 to improve skeletal muscle function as has been demonstrated in three mouse models of muscle degeneration: mdx model of Duchenne muscular dystrophy (DMD), FLExDUX4 model of facioscapulohumeral muscular dystrophy (FSHD), and a muscle injury model in wildtype mice. In all instances, treatment with SAT-3247 over a three-to-four-week period resulted in a statistically significant improvement in muscle force versus animals receiving placebo.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.47 CAD | +2.17% | +17.50% | +9.30% |
27/03 | Satellos Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
27/03 | Satellos Bioscience Announces FY 2023 Results | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.30% | 38.8M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- MSCL Stock
- News Satellos Bioscience Inc.
- Satellos Presents Positive Preclinical Efficacy Data for SAT-3247 at the 2024 MDA Clinical & Scientific Conference